@danafarber.bsky.social
A leading center for expert, compassionate cancer care and advanced research.
Appts: 877-442-3324 | http://dana-farber.org
@danafarbernews.bsky.socialReposted by @danafarber.bsky.socialCongratulations to @danafarber.bsky.social’s @nickpolizzi.bsky.social and Xin Gu, PhD, recipients of NIH New Innovator Awards supporting early career investigators pursuing highly innovative research with potential for broad impact on biomedical and behavioral science. ➡️bit.ly/4hKLs46
@danafarber.bsky.social“If you go back 20 years, metastatic lung cancer was a death sentence,” said Matthew Meyerson, MD, PhD, a lung cancer researcher and Charles A. Dana Chair in Human Cancer Genetics (II). “Now there are huge numbers of patients surviving five years, 10 years, 20 years.” Read more in the @nytimes.com ⬇
@danafarber.bsky.socialWe're proud to be included in Becker's 100 hospitals and health systems with great oncology programs 2026 list. Learn more and view the full list below.
@danafarber.bsky.socialCongratulations to @sidujain.bsky.social, a postdoctoral fellow in the Kadoch Lab, on receiving an NCI K99/R00 Pathway-to-Independence Award for his exceptional research and plans for his independent laboratory. Explore more of his work here: bit.ly/4iv3f1m
@danafarbernews.bsky.socialReposted by @danafarber.bsky.socialIn today’s @nejm.org, @danafarber.bsky.social’s @elmayermd.bsky.social is publishing results of the evERA study showing a novel combination can substantially improve disease control in patients with ER+ metastatic breast cancer compared to standard of care. ➡️bit.ly/4yoG8KS
@danafarber.bsky.socialMore than 21,000 women in the U.S. are expected to face an ovarian cancer diagnosis in 2026, according to the National Cancer Institute. As Ovarian Cancer Awareness Month comes to an end, our healing garden is illuminated teal in honor and support of those affected by the disease. 🩵
@danafarber.bsky.socialOur Pediatric Low-Grade Glioma Program is proud to partner with the Richi Foundation and Hopp Children's Cancer Center Heidelberg (KiTZ) on Richi pLGG Cure, a new transatlantic initiative to support children and families affected by pediatric low-grade gliomas (pLGG). Read more: bit.ly/4rKHXiP
@danafarber.bsky.social@lcrf.org recently honored @narjustflorezmd.bsky.social at its 2026 Gala for her tireless efforts to improve patient outcomes through research. Please join us in congratulating her on this recognition. Photo Credit: John Eng Photography
@danafarbernews.bsky.socialReposted by @danafarber.bsky.socialThe FDA voted in favor of the Galleri blood test for multicancer detection. @danafarber.bsky.social’s @drchoueiri.bsky.social tells @gohealio.bsky.social this is an important milestone, but more long-term data are needed. ➡️bit.ly/4xPVaZh
@danafarber.bsky.socialDana-Farber researchers in collaboration with 23andMe identified a rare genetic risk factor for lung cancer in people who have never smoked. The findings could help shape future screening strategies for people who carry the EGFR mutation. Read more in the @nytimes.com.
@danafarber.bsky.socialWatch the recording here:
@danafarbernews.bsky.socialReposted by @danafarber.bsky.socialIn a recent publication in the Journal of Clinical Oncology, @danafarber.bsky.social researchers found that a blood test measuring tumor DNA could help identify patients with Ewing sarcoma at higher risk of relapse, a potential tool for guiding future treatment decisions.
@danafarber.bsky.socialMagnolia Contreras, vice president of Community Health, has been named to the 2026 ALX100 list, which recognizes 100 Latino leaders making a difference across Massachusetts. Please join us in congratulating her on this recognition.
@danafarbernews.bsky.socialReposted by @danafarber.bsky.socialPARP inhibitors, radioligand therapies & immunotherapies. The treatment landscape for #ProstateCancer is changing. Dr. Mary-Ellen Taplin of @danafarber.bsky.social led the development of the first #ASCO living guideline in GU for metastatic castration-resistant prostate cancer. bit.ly/4gTIVUU
@danafarber.bsky.socialBrian Wolpin, MD, MPH, explains all things daraxonrasib after the groundbreaking FDA approval for adults with metastatic pancreatic adenocarcinoma. Listen to learn more about the science, how the trial came to be, and what’s next on @cancerletter.com: bit.ly/4Agn1nz
@danafarber.bsky.socialNew research conducted by investigators at Dana-Farber and 23andMe Research Institute shows a rare inherited mutation in the Epidermal Growth Factor Receptor (EGFR) gene is associated with a 25-fold increased risk of lung cancer.
@danafarber.bsky.socialJoin us and @pennmedicine.bsky.social for a hybrid CME: The Older Adult with Cancer on Friday, October 16 as we discuss the latest advancements in personalized care and comprehensive assessments for older adults with cancer. Register here: bit.ly/3Usp9IG
@danafarber.bsky.socialWhat goes into planning a new hospital? Our CEO and chief medical officer spoke with the Boston Business Journal about the work underway and the timeline ahead. Learn more: bit.ly/3T5ih3C
@danafarber.bsky.socialAt the @bostonglobe.com Future of Medicine Summit, @drchoueiri.bsky.social joined the panel “How Cancer Vaccines Are Rewriting the Rules of Treatment“ to discuss a new generation of cancer vaccines that have the potential to change the game.
@danafarber.bsky.socialJoin us in an overview of the current state and future direction of transplant, cellular, and gene therapies. Gain insights into emerging clinical advances, evolving care delivery models, and opportunities to enhance patient access and outcomes.
Register here: bit.ly/4iqt6HN
